Efficacy of daunorubicin encapsulated in liposome for the treatment of proliferative vitreoretinopathy

Ophthalmic Surgery Lasers and Imaging

Volumn 34, Issue 4, 2003, Pages 299-305

  Shinohara, Kohtaro ^a   Tanaka, Minoru ^b   Sakuma, Toshiro ^b   Kobayashi, Yasuhiko ^b  

^a JUNTENDO UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DAUNORUBICIN; LIPOSOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONJUNCTIVA; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; ENCAPSULATION; EXPERIMENTAL MODEL; FIBROBLAST; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOCYTE RICH PLASMA; TOXICITY TESTING; TREATMENT OUTCOME; VITREORETINOPATHY; VITREOUS BODY;

ANIMALS; CAPSULES; DAUNORUBICIN; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FUNDUS OCULI; LIPOSOMES; RABBITS; RETINA; VITREORETINOPATHY, PROLIFERATIVE;

EID: 0038602809     PISSN: 15428877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Barrada A, Peyman GA, Case J, Fishman G, Thomas A, Fiscella R. Evaluation of intravitreal 5-fluorouracil, vincristine, VP 16, doxorubicin and thiotepa in primate eyes. Ophthalmic Surg. 1984;15:767-769.
2. Blumenkranz MS, Hernandez E, Ophir A. 5-fluorouracil: new applications in complicated retinal detachment for an established antimetabolite. Ophthalmology. 1984;91:122-130.
3. Blumenkranz MS, Ophir A, Claflin AJ, Hajek A. Fluorouracil for the treatment of massive periretinal proliferation. Am J Ophthalmol. 1982;94:458-467.
4. Binder S, Riss B, Skorpik CH, Kulnig W. Inhibition of experimental intraocular proliferation with intravitreal 5-fluorouracil. Graefes Arch Clin Exp Ophthalmol. 1983;221:126-129.
5. Jarus G, Blumenkranz M, Hernandez E, Sossi N. Clearance of intravitreal fluorouracil: normal and aphakic vitrectomized eye. Ophthalmology. 1985;92: 91-96.
6. Nakagawa M, Refojo MF, Marin JF, Doi M, Tolentino F. Retinoic acid in silicon and silicon-fluorosilicone copolymer oils in a rabbit model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1994;36:2388-2395.
7. Peyman GA, Greenberg D, Fishman GA, Fiscella R, Thomas A. Evaluation of toxicity of intravitreal antineoplastic drugs. Ophthalmic Surg. 1984;15:411-413.
8. Peyman GA, Schulman J. Proliferative vitreoretinopathy and chemotherapeutic agents. Surv Ophthalmol. 1985;29:434-442.
9. Stern WH, Lewis GP, Erickson PA, et al. Fluorouracil therapy for proliferative vitreoretinopathy after vitrectomy. Am J Ophthalmol. 1983;96:33-42.
10. Sunalp M, Wiedemann P, Sorgente N, Ryan SJ. Effects of cytotoxic drugs on proliferative vitreoretinopathy in the rabbit cell injection model. Curr Eye Res. 1984; 3:619-623.
11. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 1980;90: 810-816.
12. Tano Y, Sugita G, Abrams G, Machemer R. Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol. 1980;89:131-136.
13. Martin DF, Ferris FL, Parks DJ, et al. Ganciclovir implant exchange: timing, surgical procedure, and complications. Arch Ophthalmol. 1997;115:1389-1394.
14. Marx JL, Kapusta MA, Patel SS, et al. Use of the ganciclovir implant in the treatment of recurrent cytomegalovirus retinitis. Arch Ophthalmol. 1996;114: 815-820.
15. Sanborn GE, Anand R, Torti RE, et al. Sustained release ganciclovir therapy for treatment of cytomegalovirus retinitis: use of an intravitreal device. Arch Ophthalmol. 1992;110:188-195.
16. Hashizoe M, Ogura Y, Kimura H, et al. Scleral plug of biodegradable polymers for a controlled drug release in the vitreous. Arch Ophthalmol. 1994;112:1380-1384.
17. Kimura H, Ogura Y, Hashizoe M, Nishiwaki H, Honda Y, Ikada Y. A new vitreal drug delivery system using an implantable biodegradable polymeric device. Invest Ophthalmol Vis Sci. 1994;35:2815-2819.
18. Moritera T, Ogura Y, Honda Y, Wada R, Hyon SH, Ikada Y. Microspheres of biodegradable polymers as a drug-delivery system in vitreous. Invest Ophthalmol Vis Sci. 1991;32:1785-1789.
19. Moritera T, Ogura Y, Yoshimura N, et al. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1992;33:3125-3130.
20. Assil KK, Hartzer M, Weinreb RN, Nehorayan M, Ward T, Blumenkrantz M. Liposome supression of proliferative vitreoretinopathy: rabbit model using antimetabolite encapsulated liposomes. Invest Ophthalmol Vis Sci. 1991;32:2891-2897.
21. Fiscella R, Peyman GA, Fishman PH. Duration of therapeutic levels of intravitreally injected liposome-encapsulated clindamycin in the rabbit. Can J Ophthalmol. 1987;22:307-309.
22. Joondeph BC, Peyman GA, Khoobehi B, Yue BY. Liposome-encapsulated 5-fluorouracil in the treatment of proliferative vitreoretinopathy. Ophthalmic Surg. 1988;19:252-256.
23. Simmons ST, Sherwood MB, Nichols DA, Penne RB, Sery T, Spaeth GL. Pharmacokinetics of a 5-fluorouracil liposomal delivery system. Br J Ophthalmol. 1988;72:688-691.
24. Khawly JA, Saloupis P, Hatchell DL, Machemer R. Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1991;229:464-467.
25. Wiedemann P, Kirmani M, Santana M, Sorgente N, Ryan SJ. Control of experimental massive periretinal proliferation by daunomycin: dose-response relation. Graefes Arch Clin Exp Ophthalmol. 1983;220:233-235.
26. Wiedemann P, Leinung C, Hilgers RD, Heimann K. Daunomycin and silicone oil for the treatment of proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1991;229:150-152.
27. Kikuchi H, Carlsson K, Yachi K, Hirota S. Possibility of heat sterilization of liposomes. Chem Pharm Bull. 1991;39:1018-1022.
28. Kikuchi H, Yamauchi H, Hirota S. A spray-drying method for mass production of liposomes. Chem Pharm Bull. 1991;39:1522-1527.
29. Kikuchi H, Yamauchi H, Hirota S. A polyol dilution method for mass production of liposomes. J Liposome Res. 1994;4:71-91.
30. Yamauchi H, Kikuchi H. Properties and preparation of liposomes. Fragrance Journal. 1987;87:68-76.
31. National Research Council, Institute of Laboratory Animal Resources, Commission on Life Sciences. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996. NIH Publication No. 86-23, revised 198.
32. Fastenberg DM, Diddie KR, Dorey K, Ryan SJ. The role of cellular proliferation in an experimental model of massive periretinal proliferation. Am J Ophthalmol. 1982;93:565-572.
33. Pinon RM, Pastor JC, Saomil MA, et al. Intravitreal and subretinal proliferation induced by platelet-rich plasma injection in rabbits. Curr Eye Res. 1992;11: 1047-1055.